Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.
Biosimilars· June 23, 2026 · 18 min read
By Ran Chen#Biosimilars#Oncology#FDA Approval

Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology

Biosimilars· June 21, 2026 · 6 min read
Enbrel biosimilars compared: FDA approvals, patent litigation, and the 2029 market entry
By Ran Chen#Biosimilars#FDA Approval#TNF Inhibitor

Biosimilars· June 21, 2026 · 6 min read
Soliris NMOSD Exclusivity Expiration: Skinny Label & REMS Barriers for Bkemv

Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book

Global· June 13, 2026 · 11 min read
What Canada approves: 13,428 drugs, generic DIN base, 89% domestic manufacturing
By Ran Chen#Health Canada#Biosimilars#Supply Chain

Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy

Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026

Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars

Approvals· June 10, 2026 · 10 min read
The FDA approval engine: 29,135 applications, 78% generics, and a BLA surge
By Ran Chen#FDA Approval#Generic Entry#Biosimilars